Article and Video CATEGORIES
Here's the podcast from the recent webinar by Dr. David Yankelevitz, Professor of Radiology at Mount Sinai Medical Center in New York City, on the subject of "Pulmonary Nodules: Evaluation and Management". He took us through a wonderful review of many recent developments in CT scans, both in screening programs and informal workup of many other medical settings, as well as how the best radiologists distinguish higher from lower risk nodules. He also covered the work-up of higher risk nodules with CT-guided biopsies.
One key point: a huge proportion of lung nodules aren't cancer, and as our CT scanners get more sensitive, we're going to be finding nodules in just about everyone. But when they're that common, it's not really appropriate to call them abnormal.
Below is the audio and video versions of the podcast, as well as the transcript and figures:
[powerpress]
dr-yankelevitz-pulm-nodules-evaluation-and-management-audio-podcast
dr-yankelevitz-pulm-nodules-evaluation-and-management-transcript
dr-yankelevitz-pulm-nodules-evaluation-and-management-figures
This was another webinar in the terrific expert series that we developed in partnership with LUNGevity Foundation. Thanks to both Dr. Yankelevitz and LUNGevity for making this great program possible. I hope it's helpful.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…